Zydus Cadila rises over a per cent on receiving USFDA tentative nod for cancer-treating drug

Zydus Cadila rises over a per cent on receiving USFDA tentative nod for cancer-treating drug

Ganesh V
/ Categories: Trending, Mindshare, DSIJ News

Zydus Cadila announced today that it has received tentative approval from USFDA to market Pemetrexed for injection in the strengths of 100 mg/vial, 500 mg/vial, and 1,000 mg/vial, single-dose vials.   

It is used to treat certain types of cancers such as lung cancer and mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. The drug will be manufactured at the formulation manufacturing facility at Zydus Hospira, Ahmedabad.  

Zydus Cadila Group now has 319 approvals. It has, so far, filed over 400 ANDAs since the commencement of its filing process in FY 2003-04.  

Reacting to this, the company’s stock today increased by 2.27 per cent and made an intraday high of Rs 631.75 per share. The stock of the company has increased by 74 per cent from its decline in June 2020.  

Zydus Cadila is a global pharmaceutical company that discovers, develops, manufactures & markets a broad range of healthcare therapies.  

According to BSE data, the stock traded at a P/E multiple of 42.84 and a price-to-book ratio of 4.96. The stock has a 52-week high and a 52-week low of Rs 673.70 and Rs 347.05, respectively.  

At 12.52 pm, the stock of the company was trading at Rs 624.30, up by 1.07 per cent on BSE.

Previous Article Markets in green: Broader markets outperform; Nifty Metal & Nifty PSU Bank jump over 2.5 per cent
Next Article Google & Jio Platforms develop ‘most affordable smartphone; plan to launch later this year
Rate this article:
5.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR